Search: id:"swepub:oai:DiVA.org:oru-79392" > IN-VITRO ACTIVITY O...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03693naa a2200361 4500 | |
001 | oai:DiVA.org:oru-79392 | |
003 | SwePub | |
008 | 200127s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-793922 URI |
024 | 7 | a https://doi.org/10.1136/sextrans-2019-sti.7402 DOI |
040 | a (SwePub)oru | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a vet2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Meo, Paulu Summit Therapeutics, Cambridge, UK4 aut |
245 | 1 0 | a IN-VITRO ACTIVITY OF SMT-571 AND COMPARATORS AGAINST CLINICAL ISOLATES AND REFERENCE STRAINS OF NEISSERIA GONORRHOEAE |
264 | c 2019-07-14 | |
264 | 1 | b BMJ Publishing Group Ltd,c 2019 |
338 | a print2 rdacarrier | |
520 | a Background: The emergence and spread of multidrug resistance to antibiotics used to treat gonorrhoea has resulted in a dramatic loss of effective regimens for the condition. Currently, the extended spectrum cephalosporin, ceftriaxone, is the only viable monotherapy option available, however, resistance to this last line treatment is now emerging globally. Herein, we assessed the in vitro activity of a novel small molecule antimicrobial with a new mechanism of action, SMT-571, against a large collection of N. gonorrhoeae clinical isolates and reference strains including numerous MDR and XDR gonococcal isolates.Methods: MICs (mg/L) of SMT-571 were determined by agar dilution according to current CLSI guidelines. The MICs of ceftriaxone, cefixime, azithromycin, ciprofloxacin, spectinomycin, tetracycline, and ampicillin were determined using the Etest method (AB bioMérieux, Marcy l’Etoile, France).Results: SMT-571 showed potent in vitro activity against all the tested N. gonorrhoeae isolates (n=262) with MICs ranging from 0.064 to 0.125 mg/L, and the MIC50, MIC90 and modal MIC were all 0.125 mg/L. The compound was not influenced by pre-existing resistance mechanisms with no cross-resistance or correlation between the MICs of SMT-571 and comparator agents being observed.Conclusion: This study is the first broad evaluation of the in vitro activities of a new mechanism, novel small molecule anti-microbial for the treatment of gonorrhoea. SMT-571 demonstrated highin vitroactivity against a large geographically, temporally and genetically diverse collection of clinical N. gonorrhoeae isolates and international reference strains, including various types of high-level resistant, MDR and XDR gonococcal isolates. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
700 | 1 | a Mason, Cliveu Summit Therapeutics, Cambridge, UK4 aut |
700 | 1 | a Khan, Nawazu Summit Therapeutics, Cambridge, UK4 aut |
700 | 1 | a Unemo, Magnus,d 1970-u Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län4 aut0 (Swepub:oru)muo |
700 | 1 | a Jacobsson, Susanne,d 1974-u Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län4 aut0 (Swepub:oru)sajn |
710 | 2 | a Summit Therapeutics, Cambridge, UKb Institutionen för medicinska vetenskaper4 org |
773 | 0 | t Sexually Transmitted Infectionsd : BMJ Publishing Group Ltdg 95:Suppl. 1, s. A295-A295q 95:Suppl. 1<A295-A295x 1368-4973x 1472-3263 |
856 | 4 | u https://sti.bmj.com/content/sextrans/95/Suppl_1/A295.2.full.pdfy Abstract |
856 | 4 | u https://sti.bmj.com/content/sextrans/95/Suppl_1/A295.2.full.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-79392 |
856 | 4 8 | u https://doi.org/10.1136/sextrans-2019-sti.740 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.